keyword
https://read.qxmd.com/read/38647729/establishment-of-a-novel-microfluidic-co-culture-system-for-simultaneous-analysis-of-multiple-indicators-of-gefitinib-sensitivity-in-colorectal-cancer-cells
#1
JOURNAL ARTICLE
Xin Li, Wanming Li, Jie Wang, Qun Wang, Menghu Liang, Shuo Chen, Wei Ba, Jin Fang
The therapeutic effect of gefitinib on colorectal cancer (CRC) is unclear, but it has been reported that stromal cells in the tumor microenvironment may have an impact on drug sensitivity. Herein, we established a microfluidic co-culture system and explored the sensitivity of CRC cells co-cultured with cancer-associated fibroblasts (CAFs) to gefitinib. The system consisted of a multichannel chip and a Petri dish. The chambers in the chip and dish were designed to continuously supply nutrients for long-term cell survival and create chemokine gradients for driving cell invasion without any external equipment...
April 22, 2024: Mikrochimica Acta
https://read.qxmd.com/read/38647653/preparation-of-liposome-gel-by-calcium-cross-linking-induces-the-long-term-release-of-dox-to-improve-the-antitumor-effect
#2
JOURNAL ARTICLE
Long Wang, Yi Wang, Zixuan Ye, Yitong Yu, Cheng Wang, Lin Qiu, Xuancheng Du, Shuwen Zhou, Jianhao Wang, Pengju Jiang
Doxorubicin (DOX) is one of the most commonly used anticancer drugs; however, its clinical application is greatly limited due to its toxicity and chemotherapy resistance. The delivery of DOX by liposomes (Lipos) can improve the blood circulation time in vivo and reduce toxic side effects, but the drug's accumulation in the tumor is often insufficient for effective treatment. In this study, we present a calcium cross-linked liposome gel for the encapsulation of DOX, demonstrating its superior long-term release capabilities compared to conventional Lipos...
April 22, 2024: Molecular Pharmaceutics
https://read.qxmd.com/read/38646899/strategies-and-techniques-for-preclinical-therapeutic-targeting-of-pi3kin-oncology-where-do-we-stand-in-2024
#3
REVIEW
Yanyan Liu, Qiu Sun, Xiawei Wei
INTRODUCTION: The phosphatidylinositol-3-kinase (PI3K) pathway is a crucial intracellular signaling pathway involved in cell growth, proliferation, survival, and metabolism, which is aberrant in almos<u>t</u> all types of cancer. Extensive research is dedicated to elucidating the mechanisms of action and developing PI3K inhibitors. However, only a small portion of the research has been successfully translated into clinical applications. AREAS COVERED: In this review, we present an overview of the pivotal role that the PI3K pathway plays in tumor development...
April 22, 2024: Expert Opinion on Therapeutic Targets
https://read.qxmd.com/read/38646493/non%C3%A2-coding-rna-a-promising-diagnostic-biomarker-and-therapeutic-target-for-esophageal-squamous-cell-carcinoma-review
#4
REVIEW
Longze Zhang, Yanyang Wang, Jianmei Gao, Xue Zhou, Minglei Huang, Xianyao Wang, Zhixu He
Esophageal cancer (EC) is a common form of malignant tumor in the digestive system that is classified into two types: Esophageal squamous cell carcinomas (ESCC) and esophageal adenocarcinoma. ESCC is known for its early onset of symptoms, which can be difficult to identify, as well as its rapid progression and tendency to develop drug resistance to chemotherapy and radiotherapy. These factors contribute to the high incidence of disease and low cure rate. Therefore, a diagnostic biomarker and therapeutic target need to be identified for ESCC...
June 2024: Oncology Letters
https://read.qxmd.com/read/38646426/targeting-estrogen-mediated-cyp4f2-cyp4f11-20-hete-metabolic-disorder-decelerates-tumorigenesis-in-er-breast-cancer
#5
JOURNAL ARTICLE
Juan Yang, Yin Li, Xiao Han, Tianjiao Li, Ding Li, Qiao Liu, Lizhong Yan, Fei Li, Xiaolin Pei, Ya Feng, Zhoujun Lin, Zhenkun Fu, Changjun Wang, Qiang Sun, Chenggang Li
PURPOSE: As the most common subset of breast cancer (BC), estrogen receptor positive (ER+) BC accounting for 80% of cases, has become a global public health concern. The female hormone estrogen (E2) unequivocally drives ER + breast malignancies. The reasons that estrogen affects BC development has long been considered, yet further study remains to be conducted of the molecular events in the E2-estrogen receptor α (ERα) signaling pathway in ER + BC progression, especially lipid metabolism, so providing more options for tailored and individualized therapy...
July 2024: Biochemistry and Biophysics Reports
https://read.qxmd.com/read/38645557/decoding-the-research-landscape-of-drug-resistance-and-therapeutic-approaches-in-head-and-neck-cancer-a-bibliometric-analysis-from-2000-to-2023
#6
JOURNAL ARTICLE
Qi Han, Junqi Shi, Jiaojiao Liu, Yang Fu, Zhongxun Li, Huina Guo, Xiaoya Guan, Xuting Xue, Hongliang Liu, Liting Zhao, Chunming Zhang
INTRODUCTION: Head and neck cancer is one of the most common tumors worldwide. However, drug resistance in its treatment has become a major factor limiting the efficacy. This study aims to comprehensively understand the current status of research in this field. METHODS: The study analyzes papers related to therapeutic resistance in head and neck cancer published between 2000 and 2023 in the Web of Science Core Collection To achieve the research objectives, we searched the WoSCC for research and review papers on therapeutic resistance in head and neck cancer from 2000 to 2023, screened the English literature, and analyzed the research hotspots, academic collaborations, and trends in detail using tools such as Citespace, SCImago Graphica, and VOS viewer...
2024: Frontiers in Pharmacology
https://read.qxmd.com/read/38645034/single-cell-analysis-of-treatment-resistant-prostate-cancer-implications-of-cell-state-changes-for-cell-surface-antigen-targeted-therapies
#7
Samir Zaidi, Jooyoung Park, Joseph M Chan, Martine P Roudier, Jimmy L Zhao, Anuradha Gopalan, Kristine M Wadosky, Radhika A Patel, Erolcan Sayar, Wouter R Karthaus, D Henry Kates, Ojasvi Chaudhary, Tianhao Xu, Ignas Masilionis, Linas Mazutis, Ronan Chaligné, Aleksandar Obradovic, Irina Linkov, Afsar Barlas, Achim Jungbluth, Natasha Rekhtman, Joachim Silber, Katia Manova-Todorova, Philip A Watson, Lawrence D True, Colm M Morrissey, Howard I Scher, Dana Rathkopf, Michael J Morris, David W Goodrich, Jungmin Choi, Peter S Nelson, Michael C Haffner, Charles L Sawyers
UNLABELLED: Targeting cell surface molecules using radioligand and antibody-based therapies has yielded considerable success across cancers. However, it remains unclear how the expression of putative lineage markers, particularly cell surface molecules, varies in the process of lineage plasticity, wherein tumor cells alter their identity and acquire new oncogenic properties. A notable example of lineage plasticity is the transformation of prostate adenocarcinoma (PRAD) to neuroendocrine prostate cancer (NEPC)--a growing resistance mechanism that results in the loss of responsiveness to androgen blockade and portends dismal patient survival...
April 12, 2024: bioRxiv
https://read.qxmd.com/read/38645014/increased-frequency-of-chd1-deletions-in-prostate-cancers-of-african-american-men-is-associated-with-rapid-disease-progression-without-inducing-homologous-recombination-deficiency
#8
Zoltan Szallasi, Miklos Diossy, Viktoria Tisza, Hua Li, Pranshu Sahgal, Jia Zhou, Zsofia Sztupinszki, Denise Young, Darryl Nuosome, Claire Kuo, Jiji Jiang, Yongmei Chen, Reinhard Ebner, Isabell Sesterhenn, Joel Moncur, Gregory Chesnut, Gyorgy Petrovics, Gregory T Klus, Gábor Valcz, Pier Nuzzo, Dezso Ribli, Judit Börcsök, Aurél Prósz, Marcin Krzystanek, Thomas Ried, Dávid Szüts, Kinza Rizwan, Salma Kaochar, Shailja Pathania, Alan D'Andrea, István Csabai, Shib Srivast, Matthew Freedman, Albert Dobi, Sandor Spisak
We analyzed genomic data derived from the prostate cancer of African and European American men in order to identify differences that may contribute to racial disparity of outcome and that could also define novel therapeutic strategies. In addition to analyzing patient derived next generation sequencing data, we performed FISH based confirmatory studies of Chromodomain helicase DNA-binding protein 1 ( CHD1 ) loss on prostate cancer tissue microarrays. We created CRISPR edited, CHD1 deficient prostate cancer cell lines for genomic, drug sensitivity and functional homologous recombination (HR) activity analysis...
April 1, 2024: Research Square
https://read.qxmd.com/read/38644492/an-exosomal-strategy-for-targeting-cancer-associated-fibroblasts-mediated-tumors-desmoplastic-microenvironments
#9
REVIEW
Xiaoxia Xue, Xiangpeng Wang, Mingshi Pang, Liuchunyang Yu, Jinxiu Qian, Xiaoyu Li, Meng Tian, Cheng Lu, Cheng Xiao, Yuanyan Liu
Tumors desmoplastic microenvironments are characterized by abundant stromal cells and extracellular matrix (ECM) deposition. Cancer-associated fibroblasts (CAFs), as the most abundant of all stromal cells, play significant role in mediating microenvironments, which not only remodel ECM to establish unique pathological barriers to hinder drug delivery in desmoplastic tumors, but also talk with immune cells and cancer cells to promote immunosuppression and cancer stem cells-mediated drug resistance. Thus, CAFs mediated desmoplastic microenvironments will be emerging as promising strategy to treat desmoplastic tumors...
April 21, 2024: Journal of Nanobiotechnology
https://read.qxmd.com/read/38643921/characterization-of-polyploidy-in-cancer-current-status-and-future-perspectives
#10
REVIEW
Srijonee Ghosh, Debopriya Choudhury, Dhruba Ghosh, Meghna Mondal, Didhiti Singha, Pushkar Malakar
Various cancers frequently exhibit polyploidy, observed in a condition where a cell possesses more than two sets of chromosomes, which is considered a hallmark of the disease. The state of polyploidy often leads to aneuploidy, where cells possess an abnormal number or structure of chromosomes. Recent studies suggest that oncogenes contribute to aneuploidy. This finding significantly underscores its impact on cancer. Cancer cells exposed to certain chemotherapeutic drugs tend to exhibit an increased incidence of polyploidy...
April 19, 2024: International Journal of Biological Macromolecules
https://read.qxmd.com/read/38643907/marein-a-novel-natural-product-for-restoring-chemo-sensitivity-to-cancer-cells-through-competitive-inhibition-of-abcg2-function
#11
JOURNAL ARTICLE
Yixuan Li, Fanfan Guo, Wenjing Wang, FangLin Lv, Lu Zhang, Mingxian Zhu, Shumin Yang, Shunli Dong, Mingxuan Zhou, Zhenyun Li, Zengyan Zhu, Jin-Ming Yang, Yi Zhang
The pivotal roles of ATP-binding cassette (ABC) transporters in drug resistance have been widely appreciated. Here we report that marein, a natural product from Coreopsis tinctoria Nutt, is a potent chemo-sensitizer in drug resistant cancer cells overexpressing ABCG2 transporter. We demonstrate that marein can competitively inhibit efflux activity of ABCG2 protein and increase the intracellular accumulation of the chemotherapeutic drugs that belong to substrate of this transporter. We further show that marein can bind to the conserved amino acid residue F439 of ABCG2, a critical site for drug-substrate interaction...
April 19, 2024: Biochemical Pharmacology
https://read.qxmd.com/read/38643482/estrogen-receptor-alpha-mutations-truncations-heterodimers-and-therapies
#12
JOURNAL ARTICLE
Govinda R Hancock, Jason Gertz, Rinath Jeselsohn, Sean W Fanning
Annual breast cancer (BCa) deaths have declined since its apex in 1989 concomitant with widespread adoption of hormone therapies that target estrogen receptor alpha (ERα), the prominent nuclear receptor expressed in ∼80% of BCa. However, up to ∼50% of ER + patients with high-risk disease experience post endocrine therapy relapse and metastasis to distant organs. The vast majority of BCa mortality occurs in this setting, highlighting the inadequacy of current therapies. Genomic abnormalities to ESR1, the gene encoding ERα, emerge under prolonged selective pressure to enable endocrine therapy resistance...
April 21, 2024: Endocrinology
https://read.qxmd.com/read/38643120/cancer-radioresistance-is-characterized-by-a-differential-lipid-droplet-content-along-the-cell-cycle
#13
JOURNAL ARTICLE
Francesca Pagliari, Jeannette Jansen, Jan Knoll, Rachel Hanley, Joao Seco, Luca Tirinato
BACKGROUND: Cancer radiation treatments have seen substantial advancements, yet the biomolecular mechanisms underlying cancer cell radioresistance continue to elude full understanding. The effectiveness of radiation on cancer is hindered by various factors, such as oxygen concentrations within tumors, cells' ability to repair DNA damage and metabolic changes. Moreover, the initial and radiation-induced cell cycle profiles can significantly influence radiotherapy responses as radiation sensitivity fluctuates across different cell cycle stages...
April 20, 2024: Cell Division
https://read.qxmd.com/read/38642809/synergistic-anticancer-effects-of-ginsenoside-ck-and-gefitinib-against-gefitinib-resistant-nsclc-by-regulating-the-balance-of-angiogenic-factors-through-hif-1%C3%AE-vegf
#14
JOURNAL ARTICLE
Xiaoping Song, Lina Wang, Panpan Cai, Ying Xu, Qingchao Liu, Daidi Fan
Drug resistance is a serious problem for gefitinib in the treatment of lung cancer. Ginsenoside CK, a metabolite of diol ginsenosides, have many excellent pharmacological activities, but whether ginsenoside CK can overcome gefitinib resistance remains unclear. In our study, the sensitizing activity of ginsenoside CK on gefitinib-resistant non-small cell lung cancer (NSCLC) in vitro and in vivo was investigated. Ginsenoside CK was confirmed to enhance the anti-proliferation, pro-apoptotic and anti-migration effects of gefitinib in primary and acquired resistant NSCLC...
April 18, 2024: Toxicology and Applied Pharmacology
https://read.qxmd.com/read/38642703/targeting-eed-as-a-key-prc2-complex-mediator-toward-novel-epigenetic-therapeutics
#15
REVIEW
Qichao Bao, Anil Kumar, Daqing Wu, Jia Zhou
EED within the PRC2 complex is crucial for chromatin regulation, particularly in tumor development, such that its inhibition is a promising epigenetic therapeutic strategy. Significant advancement in PRC2 inhibitor development has been achieved with an approved EZH2 inhibitor in the market and with others in clinical trials. However, current EZH2 inhibitors are limited to specific blood cancers and encounter therapeutic resistance. EED stabilizes PRC2 and enhances its activity through unique allosteric mechanisms, thereby acting as both a scaffold protein and a recognizer of H3K27me3 making it an attractive drug target...
April 18, 2024: Drug Discovery Today
https://read.qxmd.com/read/38642434/targeting-the-tumor-microenvironment-in-primary-central-nervous-system-lymphoma-implications-for-prognosis
#16
REVIEW
Han Shi, Xuefei Sun, Yuchen Wu, Qu Cui, Shengjun Sun, Nan Ji, Yuanbo Liu
Primary central nervous system lymphoma (PCNSL) is a rare extranodal non-Hodgkin lymphoma, and there is limited research on its tumor microenvironment (TME). Nevertheless, more and more studies have evidence that TME has essential effects on tumor cell proliferation, immune escape, and drug resistance. Thus, it is critical to elucidate the role of TME in PCNSL. The understanding of the PCNSL TME is gradually unfolding, including factors that distinguish it from systemic diffuse large B-cell lymphoma (DLBCL)...
April 19, 2024: Journal of Clinical Neuroscience: Official Journal of the Neurosurgical Society of Australasia
https://read.qxmd.com/read/38642246/breast-cancer-therapy-from-the-perspective-of-glucose-metabolism-and-glycosylation
#17
REVIEW
Jiaqi Zhao, Haiting Sun, Che Wang, Dejing Shang
Breast cancer is a leading cause of mortality and the most prevalent form of malignant tumor among women worldwide. Breast cancer cells exhibit an elevated glycolysis and altered glucose metabolism. Moreover, these cells display abnormal glycosylation patterns, influencing invasion, proliferation, metastasis, and drug resistance. Consequently, targeting glycolysis and mitigating abnormal glycosylation represent key therapeutic strategies for breast cancer. This review underscores the importance of protein glycosylation and glucose metabolism alterations in breast cancer...
April 20, 2024: Molecular Biology Reports
https://read.qxmd.com/read/38642158/the-endonuclease-fen1-mediates-activation-of-stat3-and-facilitates-proliferation-and-metastasis-in-breast-cancer
#18
JOURNAL ARTICLE
Min Wu, Xiaoshan Huang, Benmeng Wu, Miaolin Zhu, Yaqin Zhu, Lin Yu, Ting Lan, Jingjing Liu
BACKGROUND: The metastasis accounts for most deaths from breast cancer (BRCA). Understanding the molecular mechanisms of BRCA metastasis is urgently demanded. Flap Endonuclease 1 (FEN1), a pivotal factor in DNA metabolic pathways, contributes to tumor growth and drug resistance, however, little is known about the role of FEN1 in BRCA metastasis. METHODS AND RESULTS: In this study, FEN1 expression and its clinical correlation in BRCA were investigated using bioinformatics, showing being upregulated in BRCA samples and significant relationships with tumor stage, node metastasis, and prognosis...
April 20, 2024: Molecular Biology Reports
https://read.qxmd.com/read/38642008/diallyl-disulfide-antagonizes-dj-1-mediated-proliferation-epithelial-mesenchymal-transition-and-chemoresistance-in-gastric-cancer-cells
#19
JOURNAL ARTICLE
Jian Su, Hong Xia, Hui He, Huan Tang, Juan Zhou, Yi Xun, Fang Liu, Bo Su, Qi Su
Diallyl disulfide (DADS), an organic component of allicin abstracted from garlic, possesses multi-target antitumor activity. DJ-1 performs a vital function in promoting AKT aberrant activation via down-regulating phosphatase and tensin homologue (PTEN) in tumors. It is unknown the involvement of DJ-1 in epithelial-mesenchymal transition (EMT) of gastric cancer (GC) cells. The purpose of this study is to investigate whether diallyl disulfide (DADS) intervenes in the role of DJ-1 in GC. Based on the identification that the correlation between high DJ-1 and low PTEN expression in GC was implicated in clinical progression, we illuminated that down-regulation of DJ-1 by DADS aided in an increase in PTEN expression and a decrease in phosphorylated AKT levels, which was in line with the results manifested in the DJ-1 knockdown and overexpressed cells, concurrently inhibiting proliferation, EMT, migration, and invasion...
April 20, 2024: Environmental Toxicology
https://read.qxmd.com/read/38641421/ina03-a-potent-transferrin-competitive-antibody-drug-conjugate-against-cd71-for-a-safer-acute-leukemia-treatment
#20
JOURNAL ARTICLE
Manuela Bratti, Elisa Stubbs, Sergii Kolodych, Herve Souchet, Lois Kelly, Johanna Merlin, Michelle Marchal, Remy Castellano, Emmanuelle Josselin, Hélène Pasquer, Lina Benajiba, Alexandre Puissant, Oleksandr Koniev, Yves Collette, Coralie Belanger, Olivier Hermine, Renato C Monteiro, Pierre Launay
Innovative strategies to enhance efficacy and overcome drug resistance in hematologic cancers such as antibody-drug conjugates (ADCs) have shifted the paradigm of conventional care by delivering promising outcomes in cancer therapies with a significant reduction in the risk of relapse. The transferrin receptor 1, CD71, known to be overexpressed in malignant cells, is considered a potent anti-tumoral target. Therefore, we have developed an anti-CD71 ADC, INA03, a humanized antibody conjugated to the monomethyl auristatin E (MMAE) through a 3-arylpropiolonitrile-valine-citruline linker...
April 20, 2024: Molecular Cancer Therapeutics
keyword
keyword
171001
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.